Sensitivity analyses—cost-effectiveness acceptability curves.
These curves summarize information on uncertainty in cost-effectiveness estimates for nivolumab, pembrolizumab, and dabrafenib-trametinib. For patients with resected high-risk stage III melanoma, the willingness to pay (WTP) threshold is €50 000. ICER, incremental cost-effectiveness ratio; WTP, willingness to pay.